Atezolizumab vs BPI-371153
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
Atezolizumab
Marketed by Roche and partners
NCT02008227 · Phase 3 · completed
This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT04958811 (registry estimate)
Reported efficacy
Independent Review Facility (IRF)-Assessed Event Free Survival (EFS) (Up to approximately 96 months): IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 (missed)
Result source: NCT03456063
BPI-371153
Developed by Betta Pharmaceuticals Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05341557 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Atezolizumab
- 7 vs 5.5vs Nab-Paclitaxel+CarboplatinNCT02367781
40 other results
- 19.4 vs 16.6 NCT04513925
- 14.2 vs 13.8 NCT04513925
- 6.5 vs 5.6 NCT02367794
- 5.6 vs 5.6 NCT02367794
- 8.3 vs 9.9 NCT04619797
- 7.7 NCT02657434
- 2.8 vs 2.9 NCT03735121
- 2.8 vs 4 NCT02008227
- 2.8 vs 4.1 NCT02008227
- 2.7 vs 3.8 NCT02008227
- 8.1 vs 5 NCT02409342
- 19.4 vs 18.5 NCT04513925
- 16.7 vs 13.8 NCT04513925
- 4.6 vs 4 NCT04471428
- 4.2 vs 4 NCT03191786
- 4.2 vs 3 NCT03191786
- 8.4 vs 5.6 NCT02367794
- 7 vs 5.6 NCT02367794
- 7.1 vs 5.6 NCT02367794
- 7 vs 5.6 NCT02367794
- 9.8 vs 12.0 NCT04619797
- 11.8 vs 14.1 NCT04619797
- 6.5 NCT02367794
- 5.6 NCT02367794
- 7.3 vs 7.2 NCT04042558
- 2.7 vs 3.4 NCT01903993
- 1.7 vs 1.5 NCT03023423
- 2.7 NCT03285763
- 3.7 NCT03285763
- 4.1 NCT02848651
- 4.2 NCT01903993
- 2.7 NCT01846416
- 3.7 NCT01846416
- 2.8 NCT04426825
- 2.8 NCT04426825
- 26.1 NCT03102242
- 4.5 NCT01846416
- 2.5 NCT01846416
- 5.5 NCT01846416
- 4.3 NCT01846416
- BPI-371153
- —Not reported
OS, median
- Atezolizumab
- 13.8 vs 9.6vs DocetaxelNCT02008227
36 other results
- 15.7 vs 10.3 NCT02008227
- 13.3 vs 9.8 NCT02008227
- 14.3 vs 10.8 NCT02008227
- 16.6 vs 11.4 NCT02008227
- 19.2 vs 14.7 NCT02366143
- 19 vs 14.7 NCT02366143
- 18.6 vs 13.9 NCT02367781
- 14.2 vs 13.5 NCT02367794
- 12.6 vs 13.5 NCT02367794
- 20.5 vs 9.7 NCT02008227
- 20.2 vs 13.1 NCT02409342
- 10.7 vs 10.5 NCT04471428
- 10.3 vs 9.2 NCT03191786
- 18.9 vs 23.1 NCT04619797
- 17.5 NCT02657434
- 10.9 vs 10.1 NCT03735121
- 17 vs 13.5 NCT02367781
- 45.6 vs 45.8 NCT04513925
- 9.4 vs 10.3 NCT03191786
- 20.4 vs 14.5 NCT02367794
- 14.8 vs 14.5 NCT02367794
- 14.8 vs 15 NCT02367794
- 14.9 vs 15 NCT02367794
- 20.7 vs 33.6 NCT04619797
- 23.8 vs 33.6 NCT04619797
- 14.2 NCT02367794
- 12.6 NCT02367794
- 12.6 vs 9.7 NCT01903993
- 17.2 vs 16.8 NCT04042558
- 7.1 NCT03023423
- 11.2 NCT03285763
- 14.8 NCT02848651
- 9.3 NCT01846416
- 14.1 NCT04426825
- 14.4 NCT01846416
- 6.8 NCT01846416
- BPI-371153
- —Not reported
ORR
- Atezolizumab
- 11% vs 10.5%vs Atezolizumab IVNCT03735121
30 other results
- 13.6% vs 13.4% NCT02008227
- 17.8% vs 16.2% NCT02008227
- 13.7% vs 11.8% NCT02008227
- 60.2% vs 41% NCT02367781
- 33.9% vs 34.6% NCT04513925
- 49.7% vs 41% NCT02367794
- 38.3% vs 28.6% NCT02409342
- 45.5% vs 47.5% NCT04513925
- 37% vs 37.2% NCT04513925
- 40.9% vs 39.5% NCT04513925
- 11.8% vs 13.3% NCT04471428
- 16.9% vs 7.9% NCT03191786
- 49.3% vs 41% NCT02367794
- 50.2% vs 56.6% NCT04619797
- 51.7% NCT02657434
- 4.3% vs 13% NCT03023423
- 0% vs 7.9% NCT03977467
- 17.1% NCT02848651
- 21% NCT01846416
- 18.2% NCT04426825
- 32% NCT01846416
- 23% NCT01846416
- 15.3% vs 14.7% NCT01903993
- 11.5% NCT03285763
- 12.4% NCT03285763
- 16.7% NCT01903993
- 19% NCT01846416
- 17.4% NCT04426825
- 29% NCT01846416
- 23% NCT01846416
- BPI-371153
- —Not reported
Duration of response, median
- Atezolizumab
- 16.3 vs 6.2vs DocetaxelNCT02008227
33 other results
- 16 vs 6.2 NCT02008227
- 23.9 vs 6.3 NCT02008227
- 15.1 vs 11.2 NCT03735121
- 43.6 vs 28.1 NCT04513925
- 36.2 vs 30.2 NCT04513925
- 36.4 vs 32.4 NCT04513925
- 35.3 vs 30.2 NCT04513925
- 7.2 vs 5.2 NCT02367794
- 7 vs 5.2 NCT02367794
- 9.4 vs 11.1 NCT04619797
- 5.5 vs 4.3 NCT04471428
- 14 vs 7.8 NCT03191786
- 9.5 NCT02657434
- 6.3 vs 4.6 NCT04042558
- 18.6 vs 7.2 NCT01903993
- 2.9 vs 5.8 NCT03023423
- 16.6 NCT03285763
- 20.5 NCT03285763
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 16.3 NCT02848651
- 14.9 NCT01903993
- 17 NCT01846416
- 6.4 NCT04426825
- 6.4 NCT04426825
- 9.2 NCT01846416
- BPI-371153
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
BPI-371153: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Atezolizumab: 4 of 4 rows · BPI-371153: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Atezolizumab |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 37 more results—Arm A (Atezo+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT02409342 · Phase 3 n/a: no completion milestone NCT02367781 · Phase 3 · combination 97.9% NCT03285763 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT04513925 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT04471428 · Phase 3 · registry result, not featured evidence · combination 100%1875 mg NCT03735121 · Phase 3 · registry result, not featured evidence 38.5%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 66.7%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 53.3%1200 mg NCT03735121 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT03191786 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02657434 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm A: Atezolizumab + Paclitaxel + NCT02367794 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm B: Atezolizumab + Nab-Paclitax NCT02367794 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination 15.8% NCT04776447 · Phase 2 · registry result, not featured evidence · combination 5.6% NCT04042558 · Phase 2 · registry result, not featured evidence —Continuation Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence —Crossover Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT03977467 · Phase 2 · registry result, not featured evidence · combination 36.5% NCT02927301 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT04426825 · Phase 2 · registry result, not featured evidence · combination 16.1% NCT02716038 · Phase 2 · registry result, not featured evidence · combination 3.1% NCT03102242 · Phase 2 · registry result, not featured evidence 0% NCT03526900 · Phase 2 · registry result, not featured evidence 69.3% NCT02848651 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 1: First Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 2: Second Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 3: Third Line and Beyond At NCT02031458 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT01903993 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneAtezolizumab (MPDL3280) : 1L Parti NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 1L Part NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 2L+ Bra NCT01846416 · Phase 2 · registry result, not featured evidence · combination —Atezolizumab (MPDL3280A) : 2L+ Par NCT01846416 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneRandomized Phase: Daratumumab + At NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestoneSafety Run-in Phase: Daratumumab + NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 37 more results—Arm A (Atezo+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 — NCT02409342 · Phase 3 — NCT02367781 · Phase 3 · combination — NCT03285763 · Phase 4 · registry result, not featured evidence — NCT04513925 · Phase 3 · registry result, not featured evidence · combination — NCT04471428 · Phase 3 · registry result, not featured evidence · combination —1875 mg NCT03735121 · Phase 3 · registry result, not featured evidence —1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence —1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence —1200 mg NCT03735121 · Phase 3 · registry result, not featured evidence — NCT03191786 · Phase 3 · registry result, not featured evidence — NCT02657434 · Phase 3 · registry result, not featured evidence · combination 0.6%Arm A: Atezolizumab + Paclitaxel + NCT02367794 · Phase 3 · registry result, not featured evidence · combination 0%Arm B: Atezolizumab + Nab-Paclitax NCT02367794 · Phase 3 · registry result, not featured evidence · combination — NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination — NCT04776447 · Phase 2 · registry result, not featured evidence · combination — NCT04042558 · Phase 2 · registry result, not featured evidence —Continuation Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence —Crossover Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence 0% NCT03977467 · Phase 2 · registry result, not featured evidence · combination — NCT02927301 · Phase 2 · registry result, not featured evidence — NCT04426825 · Phase 2 · registry result, not featured evidence · combination — NCT02716038 · Phase 2 · registry result, not featured evidence · combination 3.1% NCT03102242 · Phase 2 · registry result, not featured evidence — NCT03526900 · Phase 2 · registry result, not featured evidence — NCT02848651 · Phase 2 · registry result, not featured evidence —Cohort 1: First Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence —Cohort 2: Second Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence —Cohort 3: Third Line and Beyond At NCT02031458 · Phase 2 · registry result, not featured evidence — NCT01903993 · Phase 2 · registry result, not featured evidence 9.7%Atezolizumab (MPDL3280) : 1L Parti NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 1L Part NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 2L+ Bra NCT01846416 · Phase 2 · registry result, not featured evidence · combination —Atezolizumab (MPDL3280A) : 2L+ Par NCT01846416 · Phase 2 · registry result, not featured evidence · combination —Randomized Phase: Daratumumab + At NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination —Safety Run-in Phase: Daratumumab + NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 32.8%a NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 37 more results42.5%Arm A (Atezo+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 48.3%Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 33.9% NCT02409342 · Phase 3 53.3% NCT02367781 · Phase 3 · combination 32.2% NCT03285763 · Phase 4 · registry result, not featured evidence 32.9% NCT04513925 · Phase 3 · registry result, not featured evidence · combination 41.1% NCT04471428 · Phase 3 · registry result, not featured evidence · combination 20.2%1875 mg NCT03735121 · Phase 3 · registry result, not featured evidence 15.4%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 20.5%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 26.7%1200 mg NCT03735121 · Phase 3 · registry result, not featured evidence 49% NCT03191786 · Phase 3 · registry result, not featured evidence 51.2% NCT02657434 · Phase 3 · registry result, not featured evidence · combination 45.5%Arm A: Atezolizumab + Paclitaxel + NCT02367794 · Phase 3 · registry result, not featured evidence · combination 50.3%Arm B: Atezolizumab + Nab-Paclitax NCT02367794 · Phase 3 · registry result, not featured evidence · combination 55.1% NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination 55.3% NCT04776447 · Phase 2 · registry result, not featured evidence · combination 48.5% NCT04042558 · Phase 2 · registry result, not featured evidence 13.5%Continuation Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence 8.4%Crossover Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence 100% NCT03977467 · Phase 2 · registry result, not featured evidence · combination 34.8% NCT02927301 · Phase 2 · registry result, not featured evidence 17.4% NCT04426825 · Phase 2 · registry result, not featured evidence · combination 10% NCT02716038 · Phase 2 · registry result, not featured evidence · combination 53.1% NCT03102242 · Phase 2 · registry result, not featured evidence 17.5% NCT03526900 · Phase 2 · registry result, not featured evidence 53.3% NCT02848651 · Phase 2 · registry result, not featured evidence 34.1%Cohort 1: First Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence 43.5%Cohort 2: Second Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence 44.8%Cohort 3: Third Line and Beyond At NCT02031458 · Phase 2 · registry result, not featured evidence 37.3% NCT01903993 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280) : 1L Parti NCT01846416 · Phase 2 · registry result, not featured evidence 54.8%Atezolizumab (MPDL3280A) : 1L Part NCT01846416 · Phase 2 · registry result, not featured evidence 46.2%Atezolizumab (MPDL3280A) : 2L+ Bra NCT01846416 · Phase 2 · registry result, not featured evidence · combination 49.5%Atezolizumab (MPDL3280A) : 2L+ Par NCT01846416 · Phase 2 · registry result, not featured evidence · combination 47.7%Randomized Phase: Daratumumab + At NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination 57.1%Safety Run-in Phase: Daratumumab + NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a fatigue 27.1% decreased appetite 24.6% cough 24% NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 36 more resultsalopecia 45% anaemia 36.5% nausea 32.5% NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 alopecia 47.8% nausea 37.9% fatigue 34.9% NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 cough 17.4% decreased appetite 16.9% fatigue 16.3% NCT03285763 · Phase 4 · registry result, not featured evidence pruritus 22.6% rash 20.9% cough 19.7% NCT04513925 · Phase 3 · registry result, not featured evidence · combination diarrhoea 44.9% decreased appetite 31.9% nausea 25.4% NCT04471428 · Phase 3 · registry result, not featured evidence · combination 1875 mg anaemia 19% cough 13.4% decreased appetite 12.6% NCT03735121 · Phase 3 · registry result, not featured evidence 1800 mg asthenia 38.5% cough 38.5% diarrhoea 30.8% NCT03735121 · Phase 3 · registry result, not featured evidence 1800 mg anaemia 33.3% fatigue 28.2% nausea 23.1% NCT03735121 · Phase 3 · registry result, not featured evidence 1200 mg anaemia 33.3% asthenia 20% blood cholesterol increased 20% NCT03735121 · Phase 3 · registry result, not featured evidence decreased appetite 22% cough 19.7% fatigue 19.3% NCT03191786 · Phase 3 · registry result, not featured evidence anaemia 44.3% nausea 38.5% constipation 31.6% NCT02657434 · Phase 3 · registry result, not featured evidence · combination anaemia 39.5% alopecia 39.2% fatigue 29.2% NCT02367794 · Phase 3 · registry result, not featured evidence · combination anaemia 56.3% nausea 39.2% neutropenia 36.2% NCT02367794 · Phase 3 · registry result, not featured evidence · combination anaemia 52.8% nausea 39.7% constipation 33.3% NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination neutrophil count decreased 26.3% anemia 15.8% febrile neutropenia 13.2% NCT04776447 · Phase 2 · registry result, not featured evidence · combination injection site reaction 10.3% diarrhoea 6.5% asthenia 5.2% NCT05171777 · Phase 2 · registry result, not featured evidence atrial flutter 100% dry mouth 100% dysplastic naevus 100% NCT03977467 · Phase 2 · registry result, not featured evidence · combination fatigue 43.6% procedural pain 29.8% dyspnoea 22.7% NCT02927301 · Phase 2 · registry result, not featured evidence proteinuria 30.4% aspartate aminotransferase increased 26.1% fatigue 26.1% NCT04426825 · Phase 2 · registry result, not featured evidence · combination neutropenia 50% alanine aminotransferase increased 6.7% aspartate aminotransferase increased 6.7% NCT02716038 · Phase 2 · registry result, not featured evidence · combination fatigue 65.6% nausea 53.1% dyspnea 51.6% NCT03102242 · Phase 2 · registry result, not featured evidence fatigue 44.1% nausea 27.6% decreased appetite 27% NCT02848651 · Phase 2 · registry result, not featured evidence fatigue 37.7% cough 31.9% dyspnoea 30.4% NCT02031458 · Phase 2 · registry result, not featured evidence fatigue 36.5% cough 32.1% decreased appetite 29.4% NCT02031458 · Phase 2 · registry result, not featured evidence fatigue 38.7% decreased appetite 35.9% cough 31.7% NCT01903993 · Phase 2 · registry result, not featured evidence fatigue 51.6% nausea 35.5% constipation 25.8% NCT01846416 · Phase 2 · registry result, not featured evidence constipation 46.2% fatigue 38.5% diarrhoea 30.8% NCT01846416 · Phase 2 · registry result, not featured evidence · combination fatigue 40.9% cough 35.5% dyspnoea 32.3% NCT01846416 · Phase 2 · registry result, not featured evidence · combination cough 36.4% asthenia 31.8% dyspnoea 29.5% NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 71.4% hypertension 57.1% asthenia 42.9% NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 35 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Atezolizumab
show 1 more result
show 28 more results
show 24 more results
show 17 more results
show 16 more results
show 1 more result
show 1 more result
show 1 more result
+ 834 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atezolizumab's landscape · BPI-371153's landscape